Wall Street analyst updates Nvidia stock price target

KeyBanc raised its Nvidia ($NVDA) 12-month price target to $330 from $310 while keeping an ‘Overweight’ rating, implying ~62% upside vs. ~$203 at press time. The update hinges on continued AI hardware demand despite a slight delay in the Vera Rubin platform rollout, with expectations for higher shipments of B300 GPUs and increased CoWoS advanced packaging capacity to ~1.1 million interposers next year. With 1Q FY2027 revenue at a record $81.6B (+85% YoY) and data center revenue of $75.2B (~92% of total), Street forecasts remain broadly bullish (37 analysts rated ‘Strong Buy’).

Analysis

Near term, this is more constructive for NVDA’s gross margin and revenue quality than for raw unit volume. A schedule slip that preserves a tighter high-end mix and keeps advanced packaging scarce tends to support ASPs, but it also signals that supply, not demand, is still the gating factor — which is usually the best setup for a supplier with pricing power. The market should read the target raise as confirmation that estimates are stable, not as a reason to re-rate the stock higher on its own.

The bigger second-order effect is on hyperscaler behavior. If NVDA remains supply-constrained into the next platform cycle, MSFT, AMZN, GOOGL, and META have more incentive to keep funding custom silicon and alternative accelerator paths to reduce dependency, which caps NVDA share over 6-18 months even if AI capex stays elevated. ORCL benefits only if GPU availability lets it convert backlog faster; otherwise it remains a financing-and-execution story, not a pure AI beneficiary.

For risk, the main falsifier is not the analyst target but the next earnings guide: if data center growth decelerates sharply, gross margin slips below the mid-70s, or management implies a faster normalization of packaging capacity, the bull case loses its scarcity premium. Over the next 1-3 months, the stock likely trades on earnings-prep positioning and capex commentary from hyperscalers; over 6-18 months, the key debate is whether NVDA is still the indispensable platform or just the highest-beta proxy for AI spend. Consensus is probably missing that the current setup can be simultaneously bullish for NVDA now and bearish for its long-run share if customers keep building in-house chips.

Key Decisions for Investors

• Maintain an overweight in NVDA, but add only on pullbacks into the next earnings window; the trade is about preserving exposure to scarcity-driven margin power, not chasing analyst target revisions. Falsify the thesis if data center growth or gross margin guidance cracks on the next print.
• Use any post-NVDA weakness to add selectively to MSFT, AMZN, GOOGL, and META on the view that AI capex is still monetizable for the platform owners. Best risk/reward is in MSFT and META for balance-sheet strength and operating leverage; ORCL is higher beta and needs backlog conversion confirmation.
• Do not short NVDA on the platform-delay headline alone; if you need to express skepticism, wait for evidence that hyperscalers are shifting incremental spend to custom silicon or that packaging supply is normalizing faster than expected. That would be the cleaner 1-3 month catalyst to fade NVDA.
• Set a watch item for the next NVDA earnings call and hyperscaler capex updates: if management commentary points to sustained B300 demand and no inventory build, stay with the trade; if not, cut exposure quickly because the multiple can compress fast once scarcity stops accelerating.